| Eligibility |
Inclusion Criteria:
- patients who have been diagnosed with initial or relapsed primary minimal-change
nephrotic syndrome
- patients whose urine protein-creatinine ratio (UPCR) is more than 3.0
Exclusion Criteria:
- patients whose eGFR is less than 30 ml/min/1.73 m2
- patients who were treated with immunosuppressants, such as tacrolimus, cyclosporine,
cyclophosphamide (Cytoxan), mizoribine (Bredinin), levamisole, azathioprine,
mycophenolate mofetil, or rituximab, within two weeks before the study
- patients to whom more than 10 mg prednisolone or an equivalent dose of steroid was
administered daily within two weeks before the study
- patients who are pregnant, breastfeeding, or planning to be pregnant or to breastfeed
within six months after the study completion, or who cannot or do not want to use any
contraceptive method
- patients who are hypersensitive to the investigational drug or to macrolide, such as
azithromycin, clarithromycin, or roxithromycin
- patients who were treated with a live vaccine within four weeks before the study
- patients whose liver panel laboratory test result is three times the normal range, or
acute hepatitis patients whose serum bilirubin has been clinically significantly
higher than 3.6 mg/dL for more than 1 month
- patients who have a significant general disease that makes it inappropriate for them
to participate in this study as adjudged by the investigator (e.g.,
cardiovascular-acute myocardial infarction, heart failure [classified as more than New
York Heart Association {NYHA} class III], hepatic/gastrointestinal/neurologic disease,
blood disorder, cancer, infection, renal disorder other than minimal-change nephrotic
syndrome, rheumatic arthritis with pneumonia interstitials)
- patients who have genetic problems such as galactose intolerance, Lapp lactose
deficiency, or glucose-galactose malabsorption
- patients to whom another investigational drug was administered within 30 days from the
enrollment in the study
- patients who participated in the past phases of this study
|
